{"commentary":{"count":10,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":5,"podcast":3,"x_thread":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02414139\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"NCT02414139","nct_id":"NCT02414139","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02414139. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":null,"arms":[{"description":"Pre-treated patients with MET GCN ≥ 10 treated with INC280 at 400mg BID as second or third line (2/3L)","label":"Cohort 1a: Pre-treated patients with MET GCN ≥ 10 (2/3L)","type":"EXPERIMENTAL"},{"description":"Pre-treated patients with MET GCN ≥ 6 and \\< 10 treated with INC280 at 400 mg BID as second or third line (2/3L)","label":"Cohort 1b:Pre-treated patients with MET GCN ≥ 6 and < 10 (2/3L)","type":"EXPERIMENTAL"},{"description":"Pre-treated patients with MET GCN ≥ 4 and \\< 6 treated with INC280 at 400mg BID as second or third line (2/3L)","label":"Cohort 2: Pre-treated patients with MET GCN ≥ 4 and < 6 (2/3L)","type":"EXPERIMENTAL"},{"description":"Pre-treated patients with MET GCN \\< 4 treated with INC280 at 400mg BID as second or third line (2/3L)","label":"Cohort 3: Pre-treated patients with MET GCN < 4 (2/3L)","type":"EXPERIMENTAL"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as second or third line (2/3L)","label":"Cohort 4: Pre-treated patients with MET mutation regardless of MET GCN (2/3L)","type":"EXPERIMENTAL"},{"description":"Treatment-naïve patients with MET GCN ≥10 treated with INC280 at 400mg BID as first-line (1L)","label":"Cohort 5a: Treatment-naïve patients with MET GCN ≥10 (1L)","type":"EXPERIMENTAL"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L)","label":"Cohort 5b: Treatment-naïve patients with MET mutation regardless of MET GCN (1L)","type":"EXPERIMENTAL"},{"description":"Pre-treated patients with MET GCN ≥ 10 without MET mutation treated with INC280 at 400 mg BID as second line (2L) (expansion cohort of Cohort 1a)","label":"Cohort 6.1 (expansion of Cohort 1a): Pre-treated patients MET GCN ≥ 10 without MET mutation (2L)","type":"EXPERIMENTAL"},{"description":"Pre-treated patients with MET mutation regardless of MET GCN treated with INC280 at 400 mg BID as second line (2L)(expansion of Cohort 4)","label":"Cohort 6.2 (expansion of Cohort 4): Pre-treated patients with MET mutation (2L)","type":"EXPERIMENTAL"},{"description":"Treatment-naïve patients with MET mutation regardless of MET GCN treated with INC280 at 400mg BID as first line (1L) (expansion cohort of Cohort 5b)","label":"Cohort 7 (expansion of Cohort 5b): Treatment-naïve with MET mutation regardless of MET GCN (1L)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-05-16","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":373,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Capmatinib","type":"DRUG"}],"last_update":"2024-03-20","lead_sponsor":"Novartis Pharmaceuticals","official_title":"A Phase II, Multicenter Study of Oral MET Inhibitor INC280 in Adult Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-04-12","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate (ORR) by Blinded Independent Review Committee (BIRC) Assessment","timeFrame":"Up to approximately 5 years"}],"references":[{"citation":"Wolf J, Hochmair M, Han JY, Reguart N, Souquet PJ, Smit EF, Orlov SV, Vansteenkiste J, Nishio M, de Jonge M, Akerley W, Garon EB, Groen HJM, Tan DSW, Seto T, Frampton GM, Robeva A, Carbini M, Le Mouhaer S, Yovine A, Boran A, Bossen C, Yang Y, Ji L, Fairchild L, Heist RS. Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial. Lancet Oncol. 2024 Oct;25(10):1357-1370. doi: 10.1016/S1470-2045(24)00441-8.","pmid":"39362249","type":"DERIVED"},{"citation":"Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho A, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030. Epub 2022 Dec 10.","pmid":"36822130","type":"DERIVED"},{"citation":"Wolf J, Seto T, Han JY, Reguart N, Garon EB, Groen HJM, Tan DSW, Hida T, de Jonge M, Orlov SV, Smit EF, Souquet PJ, Vansteenkiste J, Hochmair M, Felip E, Nishio M, Thomas M, Ohashi K, Toyozawa R, Overbeck TR, de Marinis F, Kim TM, Laack E, Robeva A, Le Mouhaer S, Waldron-Lynch M, Sankaran B, Balbin OA, Cui X, Giovannini M, Akimov M, Heist RS; GEOMETRY mono-1 Investigators. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020 Sep 3;383(10):944-957. doi: 10.1056/NEJMoa2002787.","pmid":"32877583","type":"DERIVED"}],"start_date":{"date":"2015-06-11","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)","url":"https://clinicaltrials.gov/study/NCT02414139"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02414139"}